Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Susan Renda & Jeffrey Freeman. (2024) You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes. Postgraduate Medicine 136:2, pages 150-161.
Read now
Read now
Articles from other publishers (28)
Faisal Al Malki, Bandar El Damanhoury, Abdallah Othman, Zain Alghamdi, Majed AlQahtani, Amr Madgy & Zahir Chouikrat. (2023)
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/
mL
in individuals with type 2 diabetes uncontrolled on basal insulin: A real‐world evidence study from Saudi Arabia (
EVOLUTION
)
. Diabetes, Obesity and Metabolism 25:10, pages 2869-2877.
Crossref
Crossref
Esra Ayan & Hasan DeMirci. (2023) A Brief Atlas of Insulin. Current Diabetes Reviews 19:6.
Crossref
Crossref
Sophie Shubow, Qin Sun, Ai Len Nguyen Phan, Dana C. Hammell, Maureen Kane, Gary H. Lyman, Allan Gibofsky, Gary R. Lichtenstein, Zachary Bloomgarden, Raymond K. Cross, Sarah Yim, James E. Polli & Yow‐Ming Wang. (2022) Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary. Clinical Pharmacology & Therapeutics 113:1, pages 37-49.
Crossref
Crossref
Gian Paolo Fadini, Raffaella Buzzetti, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Domenico Cucinotta, Gabellieri Enrico, Marangoni Alberto, Pagotto Uberto, Bongiorno Claudio, Gatta Concetta, Del Buono Andrea, Lamacchia Olga, Maiellaro Pasquale, Antenucci Daniela, Brandoni Gabriele, Borroni Francesca, Gregori Giovanna, Di Benedetto Antonino, Placentino Giuseppe, Cavalot Franco, Barale Cristina, Fadini Gian Paolo, Del Sindaco Paola, Di Loreto Chiara, Anichini Roberto, Citro Giuseppe, D’Angelo Paola, Carletti Silvia, Buzzetti Raffaella, Sterpetti Sara, Carmen Mignogna & Elli Paolo. (2022) Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetologica 59:10, pages 1317-1330.
Crossref
Crossref
Sarah Uldal, Kim Katrine Bjerring Clemmensen, Frederik Persson, Kristine Færch & Jonas Salling Quist. (2022) Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies. Nutrients 14:11, pages 2299.
Crossref
Crossref
Ahmed M. Hegab. (2022) Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs. Frontiers in Pediatrics 10.
Crossref
Crossref
Ravi Retnakaran & Bernard Zinman. (2021) The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes, Obesity and Metabolism 24:S1, pages 17-26.
Crossref
Crossref
A. V. Vitebskaya, E. V. Shreder, A. V. Popovich & E. A. Pisareva. (2021) Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon. Diabetes mellitus 24:4, pages 315-324.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2021) Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Irl B Hirsch & Boris Draznin. (2020) Transition of Patients to and from Insulin Degludec: A Clinical Challenge. The Journal of Clinical Endocrinology & Metabolism 105:6, pages e2294-e2298.
Crossref
Crossref
Sujoy Ghosh & Romik Ghosh. (2020) Glargine-300: An updated literature review on randomized controlled trials and real-world studies. World Journal of Diabetes 11:4, pages 100-114.
Crossref
Crossref
Stefano Del Prato. (2020) How conclusive is the CONCLUDE trial?. Diabetologia 63:4, pages 692-697.
Crossref
Crossref
Kuldeep Rajpoot, Muktika Tekade, Mukesh Chandra Sharma, Nagashekhara Molugulu & Rakesh K. Tekade. 2020. The Future of Pharmaceutical Product Development and Research. The Future of Pharmaceutical Product Development and Research
483
514
.
Nandu Thalange, Jens Gundgaard, Witesh Parekh & Deniz Tutkunkardas. (2019) Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. BMJ Open Diabetes Research & Care 7:1, pages e000664.
Crossref
Crossref
Neng Chun Yu. (2019) Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL. Advances in Medicine 2019, pages 1-6.
Crossref
Crossref
Vargas-Uricoechea Hernando & Frias Juan Pablo. (2019) Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 2126-2141.
Crossref
Crossref
Hernando Vargas-Uricoechea & Juan Pablo Frias. (2019) Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 1975-1989.
Crossref
Crossref
Alice Y. Y. Cheng, Dhiren K. Patel, Timothy S. Reid & Kathleen Wyne. (2019) Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Advances in Therapy 36:5, pages 1018-1030.
Crossref
Crossref
C. Lualdi, A. Silverii, I. Dicembrini, L. Pala, M. Monami & E. Mannucci. (2018) Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study. Journal of Endocrinological Investigation 42:3, pages 319-326.
Crossref
Crossref
Sudesna Chatterjee, Kamlesh Khunti & Melanie J. Davies. (2019) Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs 79:2, pages 173-186.
Crossref
Crossref
A. Philis-Tsimikas, K. Astamirova, Y. Gupta, A. Haggag, D. Roula, B.A. Bak, E.G. Fita, A.M. Nielsen & T. Demir. (2019) Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 147, pages 157-165.
Crossref
Crossref
Melanie J. DaviesDavid A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler & John B. Buse. (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:12, pages 2669-2701.
Crossref
Crossref
Elena Castellano, R. Attanasio, V. A. Giagulli, A. Boriano, M. Terzolo, E. Papini, E. Guastamacchia, S. Monti, A. Aglialoro, D. Agrimi, E. Ansaldi, A. C. Babini, A. Blatto, D. Brancato, C. Casile, S. Cassibba, C. Crescenti, M. L. De Feo, A. Del Prete, O. Disoteo, F. Ermetici, V. Fiore, A. Fusco, D. Gioia, A. Grassi, D. Gullo, F. Lo Pomo, A. Miceli, M. Nizzoli, M. Pellegrino, B. Pirali, C. Santini, S. Settembrini, E. Tortato, V. Triggiani, A. Vacirca & G. Borretta. (2018) The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen. Journal of Diabetes & Metabolic Disorders 17:2, pages 393-399.
Crossref
Crossref
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler & John B. Buse. (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:12, pages 2461-2498.
Crossref
Crossref
Barbara Predieri, Tosca Suprani, Giulio Maltoni, Vanna Graziani, Patrizia Bruzzi, Stefano Zucchini & Lorenzo Iughetti. (2018) Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes. Frontiers in Endocrinology 9.
Crossref
Crossref
Philippe Oriot, Wawrzyniak Jérémie & Martin Buysschaert. (2018) Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life. Expert Review of Endocrinology & Metabolism 13:3, pages 167-171.
Crossref
Crossref
Lori Berard, Noreen Antonishyn, Kathryn Arcudi, Sarah Blunden, Alice Cheng, Ronald Goldenberg, Stewart Harris, Shelley Jones, Upender Mehan, James Morrell, Robert Roscoe, Rick Siemens, Michael Vallis & Jean-François Yale. (2018) Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. Diabetes Therapy 9:2, pages 501-519.
Crossref
Crossref
François Chast. (2017) Nouvelles insulines : innovations moléculaires, galéniques et biopharmaceutiques. Bulletin de l'Académie Nationale de Médecine 201:7-9, pages 1255-1268.
Crossref
Crossref